Disc Medicine(IRON) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update • Presented positive data for all three programs at the European Hematology Association (EHA) 2024 Congress; demonstrated potential ef icacy for bitopertin in erythropoietic protoporphyria (EPP) and DISC-0974 in anemia of myelofibrosis (MF), as well as proof of mechanism in a Phase 1 study for DISC-3405 • Plan to provide an update on regulatory interactions for bitopertin in EPP and DISC-0974 in anemia of M ...